We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current IPN market cap is 8.89B. The company's latest EPS is EUR 4.2168 and P/E is 25.80.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 2.72B | 3.04B | 3.19B | 3.37B | 3.7B |
| Operating Income | 524.8M | 835.9M | 729.9M | 843.3M | 777.6M |
| Net Income | 548M | 646.6M | 648.6M | 644.4M | 345.9M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 4.31B | 4.99B | 5.61B | 6.32B | 6.44B |
| Total Liabilities | 2.18B | 2.25B | 2.27B | 2.5B | 2.26B |
| Total Equity | 2.13B | 2.74B | 3.34B | 3.82B | 4.18B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 771.3M | 893.4M | 971.5M | 866M | 915.5M |
| Investing | -163.7M | -332M | -458.7M | -1.07B | -676.6M |
| Financing | -307.5M | -421.8M | -164.2M | -458.3M | -100M |
| Market Cap | 8.89B |
| Price to Earnings Ratio | 25.80 |
| Price to Sales Ratio | 2.42 |
| Price to Cash Ratio | 13.16 |
| Price to Book Ratio | 2.13 |
| Dividend Yield | 1.11% |
| Shares Outstanding | 82.03M |
| Average Volume (1 week) | 98.6k |
| Average Volume (1 Month) | 94.98k |
| 52 Week Change | 4.84% |
| 52 Week High | 126.70 |
| 52 Week Low | 100.30 |
| Spread (Intraday) | 0.1 (0.09%) |
| Company Name | Ipsen SA |
| Address |
65 quai georges gorse boulogne-billancourt, hauts-de-seine 92100 |
| Website | https://www.ipsen.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
